Website
News25/Ratings3
News · 26 weeks26-29%
2025-10-262026-04-19
Mix1790d
- SEC Filings7(41%)
- Insider4(24%)
- Other2(12%)
- Earnings2(12%)
- Analyst2(12%)
Latest news
25 items- SECLENSAR Inc. filed SEC Form 8-K: Leadership Update8-K - LENSAR, Inc. (0001320350) (Filer)
- ANALYSTLENSAR upgraded by Lake Street with a new price targetLake Street upgraded LENSAR from Hold to Buy and set a new price target of $10.00
- SECSEC Form 10-K filed by LENSAR Inc.10-K - LENSAR, Inc. (0001320350) (Filer)
- SECLENSAR Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - LENSAR, Inc. (0001320350) (Filer)
- PRLENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update15 ALLY Robotic Cataract Laser Systems® ("ALLY Systems") placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025 ALLY installed base grew 48%, total laser installed base grew 13% over December 31, 2024 Recurring revenue exceeded $46.3 million for the full year; increased 15% over 2024 ORLANDO, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on key operational initiatives. "Wh
- INSIDERSEC Form 4 filed by Staab Thomas R Ii4 - LENSAR, Inc. (0001320350) (Issuer)
- ANALYSTLENSAR upgraded by BTIG Research with a new price targetBTIG Research upgraded LENSAR from Neutral to Buy and set a new price target of $10.00
- SECLENSAR Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure8-K - LENSAR, Inc. (0001320350) (Filer)
- PRAlcon and LENSAR, Inc. Agree to Terminate Merger AgreementAlcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an agreement with LENSAR, Inc. (NASDAQ:LNSR) to terminate the companies' previously announced merger agreement. "Alcon continues to believe that the acquisition of LENSAR would have significantly enhanced FLACS innovation and competition to the benefit of surgeons and patients. However, the delay and associated costs of this extended regulatory review, which began nearly a year ago, has rendered the transaction unattractive to pursue further in light of the Federal Trade Commission's opposition. Alcon remains committed to advancing cataract surgery by d
- PRLENSAR® Announces Termination of Merger Agreement with Alcon Research, LLCORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an agreement with Alcon Research, LLC ("Alcon") to terminate the merger agreement between the parties. We understand that the Federal Trade Commission intends to seek to enjoin the acquisition contemplated by the merger agreement. The Company and Alcon mutually agreed that terminating the merger agreement at this time is in the best interest of both companies, as the required closing condition of receiving necessary U.S. regulatory approvals is unli
- SECAmendment: LENSAR Inc. filed SEC Form 8-K: Other Events8-K/A - LENSAR, Inc. (0001320350) (Filer)
- SECLENSAR Inc. filed SEC Form 8-K: Other Events8-K - LENSAR, Inc. (0001320350) (Filer)
- SECLENSAR Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - LENSAR, Inc. (0001320350) (Filer)
- PRLENSAR® Provides Update on Pending Acquisition by AlconORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today provided an update on the status of its pending acquisition by Alcon Research, LLC ("Alcon"). The Company and Alcon continue to cooperate with the U.S. Federal Trade Commission (the "FTC") staff in connection with its Request for Additional Information and Documentary Material (the "Second Request") and related review of the proposed acquisition of the Company by Alcon (the "Alcon Transaction"). In light of this continued review process, the Company currently expects to
- INSIDERChief Operating Officer Connaughton Alan B. covered exercise/tax liability with 2,392 shares, decreasing direct ownership by 0.67% to 357,069 units (SEC Form 4)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERChief Financial Officer Staab Thomas R Ii covered exercise/tax liability with 1,076 shares, decreasing direct ownership by 0.63% to 170,459 units (SEC Form 4)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERChief Executive Officer Curtis Nicholas T disposed of 0 shares (SEC Form 4)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERChief Financial Officer Staab Thomas R Ii covered exercise/tax liability with 1,826 shares, decreasing direct ownership by 1% to 171,535 units (SEC Form 4)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERChief Executive Officer Curtis Nicholas T disposed of 0 shares (SEC Form 4)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERChief Operating Officer Connaughton Alan B. covered exercise/tax liability with 2,262 shares, decreasing direct ownership by 0.63% to 359,461 units (SEC Form 4)4 - LENSAR, Inc. (0001320350) (Issuer)
- SECLENSAR Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - LENSAR, Inc. (0001320350) (Filer)
- SECSEC Form SCHEDULE 13G filed by LENSAR Inc.SCHEDULE 13G - LENSAR, Inc. (0001320350) (Subject)
- SECSEC Form 10-Q filed by LENSAR Inc.10-Q - LENSAR, Inc. (0001320350) (Filer)
- SECLENSAR Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - LENSAR, Inc. (0001320350) (Filer)
- SECSEC Form DEFA14A filed by LENSAR Inc.DEFA14A - LENSAR, Inc. (0001320350) (Filer)